This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hosain, S. A. Articles by Fish, I. Search for Related Content PubMed PubMed Citation Articles by Hosain, S. A. Articles by Fish, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Use of a Calcium Channel Blocker (Nicardipine HCl) in the Treatment of Childhood Moyamoya Disease

Departments of Pediatric Neurology and Pediatric Neurosurgery, New York University Medical Center, New York, NY

John T. Hughes, MD

Departments of Pediatric Neurology and Pediatric Neurosurgery, New York University Medical Center, New York, NY

Sandra L. Forem, MD

Departments of Pediatric Neurology and Pediatric Neurosurgery, New York University Medical Center, New York, NY

Jeffrey Wisoff, MD

Departments of Pediatric Neurology and Pediatric Neurosurgery, New York University Medical Center, New York, NY

Irving Fish, MD

Departments of Pediatric Neurology and Pediatric Neurosurgery, New York University Medical Center, New York, NY

Moyamoya disease is a cerebrovascular disease characterized radiologically by progressive narrowing and occlusion of the arteries contributing to the circle of Willis and its branches. There is formation of an exuberant collateral network of blood vessels at the base of the brain, which is thought to arise in response to chronic ischemia. Clinically, the course is variable, with patients having repeated transient ischemic attacks, strokes, migraine, and seizures. Effective treatment is not available. The etiology and pathophysiology of moyamoya disease are largely unknown. Two patients with arteriographically proven moyamoya disease were identified. Both patients were symptomatic before age 5 years. Despite successful encephaloduroarteriosynangiosis revascularization procedures, they continued to experience an inexorable downhill course. A calcium channel blocker (nicardipine HCl) was introduced in order to prevent further symptoms. After the introduction of nicardipine, no further strokes occurred in either patient. There were no further episodes of transient ischemic attacks, seizures, or headache in one patient and decreased frequency in the other. In patients with moyamoya disease, nicardipine may have a beneficial effect on cerebral hemodynamics and may prevent ischemic sequelae by optimizing existing collateral circulation. (J Child Neurol 1994;9:378-380).

Journal of Child Neurology, Vol. 9, No. 4, 378-380 (1994)
DOI: 10.1177/088307389400900407


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Picture of the Month--Diagnosis Arch Pediatr Adolesc Med, February 1, 2009; 163(2): 180 - 180. [Full Text] [PDF]

				K. Aydin, C. Okuyaz, K. Gucuyener, A. Serdaroglu, and S. Akpek Moyamoya Disease Presented With Migrainelike Headache in a 4-Year-Old Girl J Child Neurol, May 1, 2003; 18(5): 361 - 363. [Abstract] [PDF]

				D. Chiu, P. Shedden, P. Bratina, and J. C. Grotta Clinical Features of Moyamoya Disease in the United States Stroke, July 1, 1998; 29(7): 1347 - 1351. [Abstract] [Full Text] [PDF]